Statement of Deviation or Variation for the half year ended on September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemant Surgical Industries has filed a routine compliance report under SEBI Listing Regulations confirming that there is no deviation or variation in the use of proceeds from its preferential issue of equity shares and convertible warrants. The company had raised Rs. 61.53 crore through this preferential issue, with allotment on September 16 and 18, 2025. Of the total Rs. 6,152 lakhs raised, only Rs. 1,543.32 lakhs (roughly 25%) has been utilized so far, while the remaining Rs. 4,609.38 lakhs is parked in the company's bank account. Funds deployed so far went only towards working capital augmentation (Rs. 788.43 lakhs out of Rs. 1,500 lakhs planned) and general corporate purposes (Rs. 754.89 lakhs out of Rs. 1,054.27 lakhs planned). No money has yet been spent on the larger planned capital expenditure (Rs. 5,000 lakhs) or debt repayment (Rs. 1,700 lakhs) objectives, with an additional Rs. 3,101.57 lakhs expected upon conversion of warrants.
This is a routine, neutral disclosure — the audit committee and auditors raised no concerns and confirmed funds are being used as originally disclosed. For shareholders, the filing signals regulatory compliance, but the slow pace of deployment towards major objectives like capex and debt repayment may be worth tracking in future quarters.